Antares Pharma Inc(ATRS) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Current Price

$3.79

RSI

30.168

Beta:

1.48428

March 02, 2021
40.9M
381K

17.399 %
5.016 %
8.754 %
22.105 %

$145,812,000
$120,315,000
$60,879,000
$53,092,000
$52,222,046
$45,658,100
21.192 %
97.630 %
14.667 %
1.666 %
14.376 %

$9,921,000
$-3,242,000
$-7,871,000
$-32,463,000
$-24,238,804
$-20,483,846
132.678 %
142.782 %
312.438 %
-25.334 %
-15.492 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.